SCHEMBL25944860

SCHEMBL25944860

c1ccc(-c2cccc(-c3ccc(-c4nc(-c5ccc6oc7ccccc7c6c5)nc(-c5cccc6sc7ccccc7c56)n4)cc3)c2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 4/20 0.38
PLA2G4A P47712 4/20 0.38
PLA2G10 O15496 1/20 0.38
PIM3 Q86V86 2/20 0.34
PIM1 P11309 1/20 0.34
CSNK2A2 P19784 1/20 0.34
CSNK2B P67870 1/20 0.34
PIM2 Q9P1W9 1/20 0.34
CHEK2 O96017 1/20 0.34
BRDT Q58F21 1/20 0.33
HSP90AA1 P07900 1/20 0.33
HSP90AB1 P08238 1/20 0.33
LIMK1 P53667 1/20 0.33
ALDH1A1 P00352 2/20 0.33
HPGD P15428 2/20 0.33
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26080460 0.99 PLA2G2A (0.39) PLA2G2APLA2G4APLA2G10PIM3PIM1
SCHEMBL25950744 0.99 PLA2G2A (0.39) PLA2G2APLA2G4APLA2G10PIM3PIM1
SCHEMBL22876271 0.97 PLA2G2A (0.37) PLA2G2APLA2G4APLA2G10PIM3PIM1
SCHEMBL19802185 0.97 PLA2G2A (0.37) PLA2G2APLA2G4APLA2G10PIM3PIM1
SCHEMBL22876268 0.97 PLA2G2A (0.37) PLA2G2APLA2G4APLA2G10PIM3PIM1
SCHEMBL19802238 0.97 PLA2G2A (0.37) PLA2G2APLA2G4APLA2G10PIM3PIM1
SCHEMBL19802241 0.97 PLA2G2A (0.37) PLA2G2APLA2G4APLA2G10PIM3PIM1
SCHEMBL22876404 0.97 PLA2G2A (0.37) PLA2G2APLA2G4APLA2G10PIM3PIM1
SCHEMBL21707328 0.97 CHEK2 (0.35) PLA2G2APLA2G4APLA2G10CHEK2BRDT
SCHEMBL26080473 0.96 PLA2G2A (0.37) PLA2G2APLA2G4APLA2G10PIM3PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT MATERIALS CO., LTD. (KR) 2023-10-05 US disclosed
US-20230312538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT MATERIALS CO., LTD. (KR) 2023-10-05 US disclosed
EP-4212526-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT Materials Co., Ltd. (KR) 2023-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME CRY1, CYP1A1, CYP1B1 PLA2G2A 3794/4885PLA2G4A 4035/4885PLA2G10 4291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.